PharmAbcine Inc. says it is receiving "remarkable" data from a Phase IIa Australian trial with tanibirumab, the South Korean bioventure’s anti-VEGFR2/KDR antibody, in an aggressive form of brain cancer.
"Our Australia trial is proceeding smoothly. Eight months of progression-free survival [PFS] in recurrent GBM [glioblastoma multiforme] patients is a...







